Arun Adlakha, MD
Pulmonary Disease · Rock Hill, SCNPI 1366435422
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $143,232 of the $183,718 with a category attached, or 78.0%. 34 manufacturers reported payments, led by Boehringer Ingelheim at 54.8% of the total. Reporting peaked in 2019 at $66,735 and has fallen 98.5% since, to $1,007 in 2025. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 942 payments — averaging $195.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$101K
- Mylan Specialty L.p.$27K
- Sanofi$24K
- Regeneron Healthcare Solutions, Inc.$15K
- Grifols USA, LLC$4K
- AstraZeneca$4K
- plus $9K from 28 others
Across 20 payments — averaging $7552.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$104K
- AstraZeneca$22K
- Chiesi USA, Inc.$9K
- GSK$8K
- Vifor (international) Ltd.$6K
- Boehringer Ingelheim$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$15,6619%
- Speaking & faculty fees$143,23278%
- Travel & lodging$9,1515%
- Food & beverage$15,3738%
- Education$3010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 156 | $100,649 |
| Mylan Specialty L.p. | 97 | $26,931 |
| Sanofi | 41 | $24,211 |
| Regeneron Healthcare Solutions, Inc. | 42 | $14,761 |
| Grifols USA, LLC | 119 | $4,148 |
| AstraZeneca(2 entities) | 132 | $3,883 |
| Paratek Pharmaceuticals, Inc. | 4 | $1,762 |
| GSK | 114 | $1,696 |
| Grifols Shared Services North America, Inc. | 1 | $1,640 |
| Teva Pharmaceuticals USA, Inc. | 55 | $718 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $683 |
| Genentech USA, Inc. | 21 | $426 |
| United Therapeutics Corporation | 15 | $364 |
| Pfizer | 17 | $325 |
| Insmed, Inc. | 15 | $267 |
| Actelion Pharmaceuticals US, Inc. | 4 | $170 |
| Verona Pharma, Inc. | 3 | $156 |
| Mallinckrodt Hospital Products Inc. | 7 | $112 |
| Circassia Inc. | 6 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $94 |
| Baxter Healthcare | 4 | $87 |
| Sunovion Pharmaceuticals Inc. | 12 | $81 |
| Advanced Respiratory, Inc | 4 | $78 |
| CSL Behring | 4 | $65 |
| Shire North American Group Inc | 3 | $49 |
| Philips North America LLC | 2 | $47 |
| Novartis | 2 | $34 |
| Amgen | 2 | $33 |
| Tersera Therapeutics LLC | 2 | $33 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Covis Pharma GmbH | 2 | $31 |
| Merck | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,718 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 94 | $1,227,181 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 414 | $519,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 411 | $461,954 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 28 | $356,141 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $241,555 |
| NucalaMepolizumab | 22 | $80,638 |
| Theophylline ErTheophylline Anhydrous | 446 | $75,161 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $60,498 |
| Pirfenidone | 30 | $54,588 |
| TezspireTezepelumab-Ekko | 12 | $48,788 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $43,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $43,274 |
| Spiriva RespimatTiotropium Bromide | 46 | $42,873 |
| Incruse ElliptaUmeclidinium Bromide | 63 | $39,593 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $35,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $100,649 | $1,305,905181 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,696 | $743,236646 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $3,883 | $554,721536 claims |
| Grifols USA, LLCProlastin C | $4,148 | $356,14128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $683 | $241,55513 claims |
| MerckDulera | $29 | $6,60411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Rock Hill
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
- Kenneth WaltersAnderson$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.